These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20029816)

  • 41. Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Jittamala P; Puthanakit T; Chaiinseeard S; Sirisanthana V
    Pediatr Infect Dis J; 2009 Sep; 28(9):826-30. PubMed ID: 19654564
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
    Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D
    J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.
    de Mulder M; Yebra G; Martín L; Prieto L; Mellado MJ; Rojo P; Muñoz-Fernández MÁ; Jiménez de Ory S; Ramos JT; Holguín A;
    J Antimicrob Chemother; 2011 Oct; 66(10):2362-71. PubMed ID: 21810838
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART.
    Oliveira AC; Martins AN; Pires AF; Arruda MB; Tanuri A; Pereira HS; Brindeiro RM
    AIDS Res Hum Retroviruses; 2009 Feb; 25(2):193-8. PubMed ID: 19239358
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.
    Dagnra AY; Vidal N; Mensah A; Patassi A; Aho K; Salou M; Monleau M; Prince-David M; Singo A; Pitche P; Delaporte E; Peeters M
    J Int AIDS Soc; 2011 Jun; 14():30. PubMed ID: 21663632
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
    Chen J; Zhang M; Shang M; Yang W; Wang Z; Shang H
    BMC Infect Dis; 2018 Nov; 18(1):571. PubMed ID: 30442114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.
    Weidle PJ; Downing R; Sozi C; Mwebaze R; Rukundo G; Malamba S; Respess R; Hertogs K; Larder B; Ochola D; Mermin J; Samb B; Lackritz E
    AIDS; 2003 Jul; 17 Suppl 3():S39-48. PubMed ID: 14565608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
    Chiappini E; Galli L; Zazzi M; de Martino M
    J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.
    Agwu A; Lindsey JC; Ferguson K; Zhang H; Spector S; Rudy BJ; Ray SC; Douglas SD; Flynn PM; Persaud D;
    AIDS Patient Care STDS; 2008 Jul; 22(7):545-52. PubMed ID: 18479228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic Diversity and Drug Resistance Among Antiretroviral Treatment-Failed Individuals from 2010 to 2012 in Honghe, China.
    Yang C; Yang S; Li J; Yang B; Liu J; Li H; Bian Z
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):822-9. PubMed ID: 25919896
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.
    Rousseau MN; Vergne L; Montes B; Peeters M; Reynes J; Delaporte E; Segondy M
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):36-43. PubMed ID: 11176267
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV-1 Drug Resistance Profiles for the HIV Protease and Reverse Transcriptase Gene in Patients Receiving Combination Therapy in Tehran, Iran.
    Sadeghi L; Lolaie M; Tabatabai RA; Bayanolhagh S; Taj L; Ahmadi NE; Abedinzadeh N; Vakili F; Ahmadi G; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):241-248. PubMed ID: 29663899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil.
    Cavalcanti AM; Lacerda HR; Brito AM; Pereira S; Medeiros D; Oliveira S
    Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):785-92. PubMed ID: 17992369
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Minority resistant HIV-1 variants and the response to first-line NNRTI therapy.
    Nicot F; Sauné K; Raymond S; Jeanne N; Carcenac R; Lefebvre C; Cuzin L; Marchou B; Delobel P; Izopet J
    J Clin Virol; 2015 Jan; 62():20-4. PubMed ID: 25542465
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
    Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
    HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monitoring of drug resistance in therapy-naïve HIV infected patients and detection of African HIV subtypes in Hungary.
    Kanizsai S; Ghidán A; Ujhelyi E; Bánhegyi D; Nagy K
    Acta Microbiol Immunol Hung; 2010 Mar; 57(1):55-68. PubMed ID: 20350879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
    Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
    J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV Drug Resistance Testing in a Resource Limited Setting with High Viral Diversity: The First Twenty Eight Months Experience.
    Ngo-Malabo ET; Ngoupo PA; Sadeuh-Mba SA; Akongnwi E; Banaï R; Ngono L; Bilong-Bilong CF; Kfutwah A; Njouom R
    Curr HIV Res; 2017; 15(4):297-305. PubMed ID: 28745207
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutations in the reverse transcriptase and protease genes of human immunodeficiency virus-1 from antiretroviral naïve and treated pediatric patients.
    Bure D; Makhdoomi MA; Lodha R; Prakash SS; Kumar R; Parray HA; Singh R; Kabra SK; Luthra K
    Viruses; 2015 Feb; 7(2):590-603. PubMed ID: 25674767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.